The following audio is from a conference call that will begin on August 07, 2014 at 10:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Vanda Pharmaceuticals ' second-quarter results were generally consistent with our expectations, as the firm reported reasonable progress for its U
outstanding, which should help ensure that his interests are well aligned with those of other shareholders. Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its key
Vanda Pharmaceuticals ( VNDA -2.8% ) Q2 results : Total Revenues: $10.9M (+31.3%); Operating Expenses: $32.5M (+177.8%); Operating
Vanda Pharmaceuticals reported first-quarter results were below our expectations because of significantly higher-than-anticipated operating costs
We're raising our fair value estimate for Vanda VNDA to $10 per share, following the announcement that orphan sleep disorder drug tasimelteon has gained priority review designation
(Reuters) - Shares of Vanda Pharmaceuticals Inc jumped nearly 42 percent on expectations that its sleep disorder drug could reach market earlier than expected after U.S. health regulators said it...
Vanda VNDA reported first-quarter results that matched our expectations for continued stagnant Fanapt growth, countered by lowered operating
Vanda VNDA reported fourth-quarter results that matched our expectations, and our attention remains focused on the upcoming catalysts for
(Reuters) - Vanda Pharmaceuticals Inc said it would stop developing its experimental drug for major depressive disorder after it failed to meet the main goal of improving symptoms in patients in a...